Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Bimzelx® (bimekizumab-bkzx) – New drug approval
October 18, 2023 - UCB announced the FDA approval of Bimzelx (bimekizumab-bkzx), for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
